Harrow, Inc. (HROW)
HROW moved a median of +0.09% 30 minutes after news, and -0.06% by the close. How HROW actually reacts to news — the realized, point-in-time move the market made, measured across 295 labeled events over the last three years with zero look-ahead.
HROW’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.09% | 53% | 294 |
| 30-min | +0.09% | 52% | 294 |
| 60-min | +0.14% | 50% | 294 |
| to close | -0.06% | 47% | 289 |
| Middle 50% of HROW reactions | -0.98% to +1.42% |
|---|---|
| Median reaction (30-min) | +0.09% |
| Measured reactions | 295 |
Half of all Harrow, Inc. news events land between -0.98% and +1.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HROW reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 17 | -0.18% | 29% | +0.58% |
| Rating reiterations | 51 | +0.04% | 51% | -0.33% |
| Price-target raises | 14 | +0.53% | 64% | +0.43% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how HROW ranks against every other measured name →
That’s how HROW usually reacts — get an email when it moves on news →Email me when HROW moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HROW's baseline. Nothing else.
Recent HROW events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K HARROW, INC. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | -0.71% | |
| Harrow Closes Acquisition of TYRVAYA® | Press release | GlobeNewswire | +0.42% | -0.71% | |
| Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO | Press release | GlobeNewswire | -0.35% | -2.59% | |
| Form 8-K HARROW, INC. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | +0.03% | |
| Harrow to Participate in Three Investor Conferences in September | Press release | GlobeNewswire | +1.55% | +0.49% | |
| Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections | Press release | GlobeNewswire | +0.76% | +1.01% | |
| Form 8-K HARROW, INC. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | -0.57% | |
| Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease | Press release | GlobeNewswire | -0.15% | -0.57% | |
| Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 | Press release | GlobeNewswire | +0.64% | -4.68% | |
| Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting | Press release | GlobeNewswire | -1.34% | -5.00% | |
| Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 | Press release | GlobeNewswire | -1.34% | -5.00% | |
| Harrow Announces Commercial Launch of BYOOVIZ® in the United States | Press release | GlobeNewswire | -0.85% | -0.88% | |
| Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow | Press release | Business Wire | -0.85% | -0.88% | |
| Form 8-K HARROW, INC. For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.70% | -1.62% | |
| Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare | Press release | GlobeNewswire | +0.02% | +7.10% | |
| Form 8-K HARROW, INC. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | +0.88% | |
| Harrow to Present at William Blair’s 46th Annual Growth Stock Conference | Press release | GlobeNewswire | +0.14% | -0.26% | |
| Form 10-Q HARROW, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.88% | -13.34% | |
| Form 8-K HARROW, INC. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -3.88% | -13.34% | |
| Harrow Announces First Quarter 2026 Financial Results | Press release | GlobeNewswire | -3.88% | -13.34% | |
| Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 | Press release | GlobeNewswire | +0.23% | +4.70% | |
| Form DEF 14A HARROW, INC. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +0.23% | +4.70% | |
| Form DEFA14A HARROW, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.23% | +4.70% | |
| Harrow Announces the Issuance of J-Code for IOPIDINE® 1% | Press release | GlobeNewswire | — | — | |
| LogiCare3PL Selected as Distribution Partner by Harrow | Press release | PR Newswire | +0.07% | -0.94% | |
| Form 8-K HARROW, INC. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | -2.12% | |
| Form 8-K HARROW, INC. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | +4.24% | |
| Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth | Press release | GlobeNewswire | +0.06% | +4.24% | |
| Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 | Press release | GlobeNewswire | +0.64% | +1.06% | |
| Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting | Press release | GlobeNewswire | -0.26% | -1.03% | |
| Form 8-K HARROW, INC. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +2.70% | +2.65% | |
| Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference | Press release | GlobeNewswire | -1.04% | +0.51% | |
| Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication | Press release | GlobeNewswire | -4.76% | -13.54% | |
| Form 10-K HARROW, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.76% | -13.54% | |
| Form 8-K HARROW, INC. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -4.76% | -13.54% | |
| Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance | Press release | GlobeNewswire | -4.76% | -13.54% | |
| Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 | Press release | GlobeNewswire | -0.88% | -0.50% | |
| Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits | Press release | GlobeNewswire | +0.11% | +7.53% | |
| OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California | Press release | Business Wire | +2.85% | +4.10% | |
| Form 8-K HARROW, INC. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | +0.62% | +1.49% | |
| Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth | Press release | GlobeNewswire | +0.62% | +1.49% | |
| Harrow to Present at Two Investor Conferences in December | Press release | GlobeNewswire | +0.03% | +0.00% | |
| Form 8-K HARROW, INC. For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +1.65% | +0.79% | |
| Harrow Announces Closing of Acquisition of Melt Pharmaceuticals | Press release | GlobeNewswire | +1.65% | +0.79% | |
| Form 10-Q HARROW, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.45% | +13.14% | |
| Form 8-K HARROW, INC. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +3.45% | +13.14% | |
| Harrow Announces Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +3.45% | +13.14% | |
| Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 | Press release | GlobeNewswire | +0.34% | -1.44% | |
| Form 8-K HARROW, INC. For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | -6.91% | |
| ImprimisRx Announces Leadership Changes | Press release | GlobeNewswire | -1.41% | -6.91% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HROW section they belong to.
Where else HROW is measured.
HROW earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Harrow, Inc.'s median reaction calculated?
Every labeled HROW news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 295 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of HROW's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HROW's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.